Rankings
▼
Calendar
ICCC
ImmuCell Corporation
$60M
Q1 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$4M
+53.1% YoY
Gross Profit
$2M
49.9% margin
Operating Income
$265,304
6.0% margin
Net Income
$144,555
3.3% margin
EPS (Diluted)
$0.03
QoQ Revenue Growth
+50.2%
Cash Flow
Operating Cash Flow
$677,197
Free Cash Flow
$482,794
Stock-Based Comp.
$82,835
Balance Sheet
Total Assets
$40M
Total Liabilities
$10M
Stockholders' Equity
$30M
Cash & Equivalents
$11M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$4M
$3M
+53.1%
Gross Profit
$2M
$1M
+61.9%
Operating Income
$265,304
-$178,155
+248.9%
Net Income
$144,555
-$221,123
+165.4%
← FY 2019
All Quarters
Q2 2019 →
ICCC Q1 2019 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena